Exelixis, Inc.
HealthcareNASDAQ:EXEL · NASDAQ Global Select
-$0.37 today
Vol 1.58M · Avg 2.56M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
36.2%
avg 27.6%
ROIC
29.7%
avg 9.6%
ROA
27.5%
avg 9.0%
Analysis
ROE is currently the strongest return metric at 36.2% versus its period average of 27.6%. 3 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Brenda Hefti | Senior VP & General Counsel | $2.94M | — | 52 | $106,762.00 | 0.04% |
Michael Morrissey | Chief Executive Officer, President & Director | $2.70M | — | 65 | $1.36M | 0.54% |
Christopher J. Senner | Executive Vice President & Chief Financial Officer | $1.30M | — | 58 | $50,649.00 | 0.02% |
Dana T. Aftab | Executive Vice President of Research & Development | $1.07M | — | 62 | $594,741.00 | 0.24% |
Patrick J. Haley | Executive Vice President of Commercial | $959,624.00 | — | 50 | $50,649.00 | 0.02% |
Deborah Burke | Senior Vice President of Finance & Controller | $459,323.00 | — | 70 | — | — |
Stelios Papadopoulos | Co-Founder & Independent Chair of the Board | $137,750.00 | — | 78 | $1.20M | 0.48% |
Stefan Krauss | Vice President & Head of Business Development | — | — | — | — | — |
William Berg | Senior Vice President of Medical Affairs | — | — | — | — | — |
Andrew Ross Peters | Senior Vice President of Strategy | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
1
$1.19M
Sells
31
$41.72M
Net Sentiment
$40.53M
Net selling
Most Active
Haley Patrick J.
7 transactions
1–10 of 32
Analysis
Insiders reported 1 buys worth $1.19M and 31 sells worth $41.72M over the last 12 months. That adds up to net selling of $40.53M. Haley Patrick J. was the most active insider with 7 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A10 analysts |
| Revenue | N/A | N/A | -7.8% | +31.6% (16yr)11 analysts |
| Net Income | N/A | N/A | N/A | N/A11 analysts |
| EBIT | N/A | N/A | N/A | N/A11 analysts |
Analysis
Recent growth has been strongest in Revenue at -7.8% over three years. Forward estimates point to Revenue at +31.6% (16yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Revolution Medicines, Inc.
NASDAQ:RVMD
$32.71B
Moderna, Inc.
NASDAQ:MRNA
$19.80B
BridgeBio Pharma, Inc.
NASDAQ:BBIO
$13.08B
Align Technology, Inc.
NASDAQ:ALGN
$12.52B
Madrigal Pharmaceuticals, Inc.
NASDAQ:MDGL
$11.08B
BioMarin Pharmaceutical Inc.
NASDAQ:BMRN
$10.81B
Bio-Techne Corporation
NASDAQ:TECH
$8.45B
Halozyme Therapeutics, Inc.
NASDAQ:HALO
$8.24B
Caris Life Sciences, Inc.
NASDAQ:CAI
$5.08B
Atrium Therapeutics, Inc.
NASDAQ:RNA
$211.60M
Who manages EXEL?
Exelixis, Inc. (EXEL) lists 10 active executives. The top listed executive is Patrick J. Haley, Executive Vice President of Commercial.
Are EXEL insiders buying or selling?
Recent insider activity shows net selling of $145.36M.
Explore More
Continue the stock analysis
Jump to another research area for this company.